Zoetis Inc
For the period ended Dec 31, 2024. Filed Feb 13, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 13, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Manufacturing and Supply Chain
Our products are manufactured at sites operated by us and sites operated by third-party contract manufacturing organizations, which we refer to as CMOs. We have a global manufacturing network of 22 sites operated by us.
Our global manufacturing network is comprised of the following sites:
| Site | Location | Site | Location |
|---|---|---|---|
| Buellton | California, U.S. | Olot | Spain |
| Campinas | Brazil | Overhalla | Norway |
| Catania | Italy | Rathdrum | Ireland |
| Charles City | Iowa, U.S. | Rutherford | Australia |
| Durham | North Carolina, U.S. | San Diego | California, U.S. |
| Farum | Denmark | Suzhou | China |
| Kalamazoo | Michigan, U.S. | Tallaght | Ireland |
| Klofta | Norway | Tullamore | Ireland |
| Lincoln | Nebraska, U.S. | Union City | California, U.S. |
| Louvain-la-Neuve | Belgium | Wellington | New Zealand |
| Melbourne | Australia | White Hall | Illinois, U.S. |
We own the majority of these sites, with the exception of our facilities in Buellton, California (U.S.), Durham, North Carolina (U.S.), Klofta (Norway), Melbourne (Australia), San Diego, California (U.S.), and Union City, California (U.S.), which are leased sites. In addition, a portion of our facilities in Tullamore (Ireland) is leased.
7 |
We regularly evaluate the adequacy of our manufacturing capabilities. We are currently in the process of expanding these capabilities at certain existing sites. Additionally, we purchased a manufacturing site outside Atlanta, Georgia in 2023, where we plan to begin commercial production in the future. In 2024, we ceased all operations at our Weibern, Austria site, and completed the divestiture of our medicated feed additive product portfolio, certain water soluble products and related assets, which included sites manufacturing those products in Chicago Heights, Illinois (U.S.); Eagle Grove, Iowa (U.S.); Medolla, Italy; Salisbury, Maryland (U.S.); Suzhou, China; and Willow Island, West Virginia (U.S.).
Our global manufacturing and supply chain is supported by a network of CMOs. As of December 31, 2024, this network was comprised of over 110 CMOs, including those centrally-managed as well as locally-managed CMOs.
We select CMOs based on several factors: (i) their ability to reliably supply products or materials that meet our quality standards at an optimized cost; (ii) their access to niche products and technologies; (iii) capacity; and (iv) financial efficiency analyses. Our regional and global manufacturing teams seek to ensure that all of the CMOs we use adhere to our standards of manufacturing quality.
We purchase certain raw materials necessary for the commercial production of our products from a variety of third-party suppliers. We utilize logistics service providers as a part of our global supply chain, primarily for shipping and logistics support.
We intend to continue our efficiency improvement programs in our manufacturing and supply chain organization, including Six Sigma and Lean capabilities, which are processes intended to improve manufacturing efficiency. We have strong globally managed and coordinated quality control and quality assurance programs in place at our global manufacturing network sites, and we regularly inspect and audit our global manufacturing network and CMO sites.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.